Business Wire

COMPUTEX 2021 Hybrid Embarks on an Intelligent Journey with AI Tech Giants

Share

According to IDC, worldwide revenues for the artificial intelligence (AI) market are expected to break the USD 500 billion mark. As AI continues to transform daily lives with various applications, industries are actively introducing AI technologies into operations in the drive to optimize business processes. As the global leading ICT tradeshows, COMPUTEX teams up with major international technology companies to showcase the AI ecosystem and deliver an exceptional intelligent exhibition experience.

AI is the ‘it’ topic at COMPUTEX 2021 Hybrid

COMPUTEX organizer, the Taiwan External Trade Development Council (TAITRA), states that AI is one of the hottest topics at COMPUTEX 2021 Hybrid this year, especially as 5G providers inject new momentum into a variety of developments in AI and IoT technology applications.

At the #COMPUTEXVirtual online exhibition, GIGABYTE will showcase extensive product lines based on multiple processor architectures for a variety of applications. By empowering the CPUs with external accelerators such as ASICs, FPGAs, and GPUs, GIGABYTE offers complete solutions for AI learning and AI inferencing, expediting the actualization of the AIoT.

Supermicro will showcase the latest multi-GPU optimized systems that deliver advanced solutions to AI, Deep Learning, HPC, 3D-Graphics Visualization, Desktop Virtualization, and Video Streaming applications.

On the other hand, GARAOTUS from the on-premise HPC cloud solution provider, SYSTEX, will offer HPC and AI solutions with cloud-native that simplify the customers’ business workflow, increase productivity, and reduce the labor-intensive burden to accelerate innovation.

AI has acted as the main driver of emerging technologies, the COMPUTEX Forum will focus on AI’s developments and trends as one of the topics. Following the announcements of a number of the latest AI technologies at the GPU Technology Conference (GTC21), NVIDIA plans to share transformative technologies that will make impacts on various industries with global participants in the COMPUTEX keynote and forum.

In addition, NXP Semiconductors will share its vision and lead the Secure Edge and AI Empowerment discussions in fields such as Smart Home, Smart City, Smart Transportation, and Smart Manufacturing in the COMPUTEX Forum as well.

#COMPUTEXVirtual to build the intelligent platform for a personalized experience

Having partaken in every industry disruption within the last four decades, COMPUTEX now rides the digital transformation wave with tech pioneers. This year, COMPUTEX has chosen Appier, a Taiwanese unicorn startup listed in the Tokyo Stock Exchange, as its technology partner. Leveraging Appier’s AI and automation technologies to create the optimal digital user journey, #COMPUTEXVirtual helps exhibitors easily manage multiple marketing channels through a one-stop platform, while providing a more personalized interactive experience to all visitors. Exhibitors can reach people with the most relevant content and achieve optimal engagement to increase business collaboration opportunities with their target audiences.

#COMPUTEXVirtual and #InnoVEXVirtual online exhibitions are now open for registration. TAITRA will soon release more details on the upcoming COMPUTEX 2021 Hybrid.

For more updates:

COMPUTEX website: https://www.computextaipei.com.tw/
InnoVEX website : https://www.innovex.com.tw/

About COMPUTEX TAIPEI (also called COMPUTEX):

Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.

About COMPUTEX 2021 Hybrid:

As a pioneer in technology, COMPUTEX has been on the forefront in embracing digital transformation. COMPUTEX will launch the Online-Merge-Offline (OMO) exhibition platform "COMPUTEX 2021 Hybrid" in 2021. As the event organizer, the Taiwan External Trade Development Council (TAITRA) aims to deliver an exceptional exhibition experience by combining #COMPUTEXVirtual with the onsite exhibition. In collaborating with the Taiwanese unicorn startup, Appier, TAITRA is introducing AI computing capabilities to the exhibition to shape COMPUTEX as a global model.

About TAITRA:

Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press Contacts:
Ms. Tessa Lin <tessalin@taitra.org.tw>
Ms. Li Chao < lichao@taitra.org.tw>

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release

Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye